ACARIX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3325 SEK | +2.47% |
|
+8.84% | +75.18% |
| 05-14 | Transcript : Acarix AB, Q1 2024 Earnings Call, May 14, 2024 | |
| 05-14 | Acarix AB Approves Board Elections | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +75.18% | 24.04M | D+ | ||
| -18.82% | 18.18B | A | ||
| -44.00% | 2.84B | C+ | ||
| +23.49% | 1.94B | - | ||
| -3.70% | 1.64B | - | ||
| +31.41% | 1.33B | B+ | ||
| -16.85% | 953M | - | ||
| -23.12% | 891M | - | C- | |
| +3.17% | 865M | - | ||
| +24.76% | 543M | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- ACARIX Stock
- Ratings Acarix AB